Shimizu Masayuki, Takayama Shin, Kikuchi Akiko, Arita Ryutaro, Ono Rie, Ishizawa Kota, Ishii Tadashi
Shimizu Clinic, Sendai, Japan.
Department of Kampo Medicine, Tohoku University Hospital, Sendai, Japan.
Front Nutr. 2021 Aug 12;8:702812. doi: 10.3389/fnut.2021.702812. eCollection 2021.
The present report aims to investigate the use of Kampo medicine for advanced pancreatic cancer patients in order to prolong survival. We retrospectively reviewed medical records of patients with pancreatic cancer who presented to our Shimizu Clinic from 2000 to 2020. Patients who survived at least twice as long as the initial prognostic estimate were selected and their treatment was reviewed. The Kampo formula and crude drugs were selected according to the Kampo diagnosis and treatment strategy, which included qi and blood supplementation; qi, blood and water smoothing; and inflammation (termed "heat") and cancer suppression. Ten patients aged 45-80 years (six males and four females) with stage IV advanced cancer were selected. All patients received hozai, which is a tonic formula, of juzentaihoto (JTT) or hochuekkito (HET) decoction. Anti-cancer crude drugs were included in the decoctions of nine patients. At the first visit, the estimated life expectancy for all patients was no more than 1 year; however, treatment with Western and Kampo medicine led to a relatively long survival period of over 2 years. Three patients were still living at the time of this writing, more than 2, 6, and 14 years after treatment initiation. Our results suggest that Kampo medicine may be useful for disease control and supportive care for patients with advanced pancreatic cancer.
本报告旨在研究汉方医学对晚期胰腺癌患者的应用，以延长生存期。我们回顾性分析了2000年至2020年在我们清水诊所就诊的胰腺癌患者的病历。选择生存期至少是初始预后估计两倍的患者，并对其治疗进行回顾。根据汉方诊断和治疗策略选择汉方配方和生药，包括补气养血、气血水通畅、清热（称为“热”）和抗癌。选择了10例年龄在45 - 80岁的IV期晚期癌症患者（6例男性和4例女性）。所有患者均接受了扶正方剂，即十全大补汤（JTT）或补中益气汤（HET）煎剂。9例患者的煎剂中包含抗癌生药。初诊时，所有患者的预期寿命均不超过1年；然而，中西医结合治疗使生存期相对延长至2年以上。在撰写本文时，有3例患者仍在世，分别在开始治疗后的2年、6年和14年以上。我们的结果表明，汉方医学可能对晚期胰腺癌患者的疾病控制和支持治疗有用。
